Campaigners say US govt should have remdesivir patent rights

The PrEP4All campaign has argued that the US government should own joint patent rights for remdesivir, the Gilead Sciences antiviral which is the only drug approved anywhere for treating COVID-19.

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Americas

Why the US is poised for a patent litigation surge in 2026

12 January 2026 After “seismic” changes imposed by the USPTO last year, litigating patents will become significantly more difficult and costly to defend, and both plaintiffs and defendants must urgently retool their strategies, advise lawyers from BCLP.

Americas

From migraine drugs to COVID vaccine spats, US lawsuits pile up

9 January 2026 A busy week in US courts saw major pharma companies and biotech firms move to protect key therapies and research tools, with new lawsuits over migraine and cancer drug generics, and alleged misuse of COVID-19 vaccine tech.

Americas

Insulin pump rivals face off in major trade secrets dispute hearing

8 January 2026 Important questions about when companies must act on suspicions of theft and whether damages can stack with injunctions were raised in a dispute that has already sent ripples across med tech.

More features

Senior USPTO solicitor steps into private practice

Goodwin targets transatlantic patent work with London hire

Bayer secures key Denmark ruling as Xarelto faces expiry pressure

Carpmaels & Ransford builds Munich UPC team with elite hire

Why the US is poised for a patent litigation surge in 2026

From migraine drugs to COVID vaccine spats, US lawsuits pile up

How AI will be shaped by legal and regulatory developments in 2026

Deadline extended: Who are the world’s best in-house counsel?

Campaigners say US govt should have remdesivir patent rights

More on this story

Editor's picks

Editor's picks

More features